Dr. Rupenthal is an innovator in ocular drug delivery ideas. Her current research, co-funded by a Sir Charles Hercus Health Research Fellowship from the New Zealand Health Research Council, focuses predominantly on the development of stimuli-response ocular drug delivery systems with projects investigating implants responsive to ultrasound, light or a small electrical current. Since 2013, it has been aim of the Buchanan Ocular Therapeutics Unit (BOTU) to translate ocular therapeutic related scientific research into the clinical setting, whether pharmaceutical, cell or technology based. This presentation (ca. 45 minutes) will give an overview of the research performed by BOTU team members investigating novel therapeutics and innovative drug delivery systems in the area of dry eye, diabetic retinopathy and age-related macular degeneration management.